Loading... Please wait...

Entera Bio Ltd. (ENTX) Stock Price, News & Analysis

Currency in USD Disclaimer
$1.68 $0.01 (0.6%)
$1.63
$1.71
$0.52
$3.35

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company


  • Altman Z Score 10.16
  • Piotroski Score 3.00
  • Grade Buy

Company brief: Entera Bio Ltd. (ENTX)


Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Price Target and Rating


  • $0.00
  • $0.00
  • $0.00
  • N/A
  • Buy
  • N/A
  • N/A

Profitability


  • -$0.28
  • -7.14
  • -7.14
  • -7.14
  • $-8,889,000

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.


Latest News of ENTX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.


×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Log In


or

Continue with Google Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.